Q&A: Atsena Therapeutics’ gene therapy for inherited blindness shows promise
Seven years after the FDA approved Luxterna, scientists have yet to bring another congenital blindness treatment to the market.
A team of researchers from the Perelman School of Medicine at the University of Pennsylvania aims to change this. The group recently published a study in The Lancet documenting their success using gene therapy to treat an inherited retinal blindness that affects as many as 100,000 people globally.
